Comparing the survival rate of different chemotherapy protocols with ETV6/RUNX1-positive children, we found that the estimate EFS and OS in pediatric patients receiving the SCCLG-ALL-2016 protocol were significantly higher than in those receiving the GD-ALL-2008 protocol (EFS: 96.64 ± 2.2% vs 88.97 ± 4.62%, P=0.011; OS: 97.48 ± 1.99% vs 91.82 ± 4.07%, P=0.049, respectively) (Figures 2A, B). The gene discussed is ETV6; the disease is acute lymphoblastic leukemia.